Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 11/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | CFD | P00746 | 7/20 | 0.55 |
| ▸ | F11 | P03951 | 2/20 | 0.55 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396992 | 0.85 | SUCNR1 (0.60) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL16410307 | 0.84 | CFD (0.69) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL16396967 | 0.81 | CFD (0.82) | SUCNR1CFDF11TPSB2 | |
| SCHEMBL17764496 | 0.80 | CFD (0.55) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL16397314 | 0.80 | SUCNR1 (0.49) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL17764462 | 0.79 | SUCNR1 (0.48) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL16397193 | 0.78 | SUCNR1 (0.47) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL21455907 | 0.77 | SUCNR1 (0.45) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL16396204 | 0.77 | SUCNR1 (0.46) | SUCNR1HDAC1CFDF11TPSB2 | |
| SCHEMBL21545194 | 0.77 | SUCNR1 (0.48) | SUCNR1HDAC1CFDF11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | SUCNR1 4670/4885HDAC1 3377/4885CFD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.